Press release content from Globe Newswire. The AP news staff was not involved in its creation. Dresner Partners Advised JADE Biomedical (China) on Investment by and Partnership with Charles ... Dresner PartnersFebruary 17, 2021 GMT SILICON VALLEY, Calif. and SHANGHAI, China, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Dresner Partners, a leading FINRA-registered, middle-market investment bank and Mergers Alliance member firm, is pleased to announce that it advised JADE Biomedical™ of China (JADE). Charles River Laboratories (CRL) has made an equity investment in JADE and formed a strategic business partnership to expand worldwide joint biologics quality and clinical testing capabilities. JADE is a provider of end-to-end quality management services for the biopharmaceutical industry. The partnership will expand CRL’s biologics testing capabilities geographically and help to accommodate demand for biologics therapeutics, especially cell and gene therapies, reaffirming the company’s commitment as a global development partner. This strategic relationship will also enable JADE to expand their current global Good Manufacturing Practice (GMP) product testing operations in Shanghai into a second facility and further build upon its current offering of comprehensive biologics quality management and testing services.